A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia
| Autor: | Zhi-chao Chen, Ling-hui Xia, Qiu-bai Li, Yong You, Ping Zou, Lei Li |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Transplantation Conditioning Premedication medicine.medical_treatment Graft vs Host Disease idarubicin Hematopoietic stem cell transplantation etoposide Gastroenterology high-risk acute leukemia allogeneic stem cell transplantation Risk Factors hemic and lymphatic diseases High Risk Acute Leukemia Antineoplastic Combined Chemotherapy Protocols Hydroxyurea Pharmacology (medical) Acute leukemia Leukemia Graft Survival Cytarabine Hematopoietic Stem Cell Transplantation General Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma Total body irradiation Combined Modality Therapy Semustine Leukemia Myeloid Acute Aspergillus Treatment Outcome Hematologic Neoplasms Acute Disease Female Immunosuppressive Agents Whole-Body Irradiation medicine.drug Mucositis China medicine.medical_specialty Cyclophosphamide Methylprednisolone Article Disease-Free Survival Internal medicine medicine Humans Transplantation Homologous Idarubicin Busulfan Retrospective Studies Pharmacology intensified conditioning regimen business.industry Pneumonia Surgery Transplantation business |
| Zdroj: | Acta Pharmacologica Sinica |
| ISSN: | 1745-7254 1671-4083 |
| DOI: | 10.1038/aps.2009.132 |
| Popis: | Aim: To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia. Methods: From January 2005 to June 2008, 48 consecutive patients (male: n=29; median age: 30 years, range 14–51 years) with high-risk acute leukemia underwent allo-SCT following an IDA- or VP16-intensified conditioning regimen. The conditioning regimens were modified BUCY2 (busulfan+cyclophosphamide) consisting of IDA (15 mg/m2 per day, days -12 to -10) or VP16 (25 mg/kg per day, days -3 to -2) and CY/TBI (cyclophosphamide/total body irradiation) intensified with IDA (15 mg/m2 per day, days -6 to -5) or VP16 (25 mg/kg per day, days -3 to -2) for acute myeloid leukemia and acute lymphoblastic leukemia, respectively. Results: Between the two groups, no significant differences in terms of baseline characteristics, incidence of acute or chronic graft-versus-host disease (GVHD) or transplant-related mortality (TRM) (P=0.50) were observed. However, the IDA group demonstrated higher incidences of mucositis and Aspergillus pneumonia (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|